Chimerix, Inc. (NASDAQ:CMRX) headquartered in Durham, will host a conference call for the investment community to discuss the 2Q20 earnings result on 10th August 2020 at 8:30 AM Eastern Time.
Those interested in listening to the conference call live via the Internet can visit www.chimerix.com
Earnings Expectation
Chimerix, Inc. is reporting second quarter financial results on Monday 10th August 2020, before market open.
According to analysts surveyed by Thomson Reuters, CMRX is expected to report 2Q20 loss of $ 0.17 per share from revenue of $ 1.06 million.
For the full year, analysts anticipate top line of $ 4.40 million, while looking forward to loss of $ 0.75 per share bottom line.
Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The companys lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. It is also developing CMX521, a nucleoside for the treatment of norovirus; and CMX157, a nucleoside analog for the treatment of HIV and hepatitis B virus infection.
